A Crisis in Clinical Research

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2024 Jul 11

PMID 38991727

Authors

David S Hong

Patricia LoRusso

Mario Sznol

Affiliations

Soon will be listed here.

Abstract

The clinical research pipeline is critical to ensuring continued development of novel treatments that can offer patients with cancer safe and effective options. Unfortunately, progress has slowed since the COVID-19 pandemic due to uncovered, systemic inefficiencies across critical processes. Towards initiating discussion on how to reinvigorate clinical research, the Society for Immunotherapy of Cancer (SITC) hosted a virtual summit that characterized issues and formed potential solutions. This commentary serves to highlight the crisis facing clinical research as well as stimulate field-wide discussion on how to better serve patients into the future.

Citing Articles

Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement.

Thota R, Hurley P, Miller T, Bruinooge S, Lipset C, Harvey R J Clin Oncol. 2024; 42(33):3986-3995.

PMID: 39079075 PMC: 11568957. DOI: 10.1200/JCO.24.00961.

References

Brown D, Wobst H, Kapoor A, Kenna L, Southall N . Clinical development times for innovative drugs. Nat Rev Drug Discov. 2021; 21(11):793-794. PMC: 9869766. DOI: 10.1038/d41573-021-00190-9. View

Upadhaya S, Neftelinov S, Hodge J, Campbell J . Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nat Rev Drug Discov. 2022; 21(7):482-483. DOI: 10.1038/d41573-022-00030-4. View

Califf R . Now is the time to fix the evidence generation system. Clin Trials. 2023; 20(1):3-12. DOI: 10.1177/17407745221147689. View